Gilead Sciences to acquire ADC developer Immunomedics for $21bn
As per the terms of the deal, Gilead Sciences has offered to acquired 100% of Immunomedics for $88 per share in cash. Through the acquisition, Gilead Sciences gets
As per the terms of the deal, Gilead Sciences has offered to acquired 100% of Immunomedics for $88 per share in cash. Through the acquisition, Gilead Sciences gets
The FDA-approved strength for both COPD and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25mcg. There is an additional strength for asthma alone which is fluticasone furoate
The agreement comes as Exelixis continues to build out its pipeline behind CABOMETYX (cabozantinib), its flagship product that is now a global oncology franchise. Under the terms of
AZD1222, which is currently in phase 3 trials, has been seen as one of the most promising vaccine candidates across the world that is likely to be approved
This strategic financing allows Cycle to build on the success of NITYR (nitisinone) Tablets, which treats patients with the rare genetic metabolic disease, hereditary tyrosinemia type 1. Cycle’s
The German company said that 41% of PAH patients transitioning to Adempas therapy after inadequate response to phosphodiesterase-5 inhibitors (PDE5 inhibitors) achieved the composite primary endpoint, which is
The post hoc analysis from the pivotal Phase III IRIDIUM study—presented virtually at the European Respiratory Society (ERS) International Congress 2020— also showed the safety profile for high-dose
Alkahest is a clinical stage company that is focussed on the discovery and development of treatments for neurodegenerative and age-related diseases with therapies that target the aging plasma
PANS is a condition defined by sudden onset of obsessive-compulsive symptoms and/or severe eating restrictions, along with at least two other cognitive, behavioral, or neurological symptoms, according to
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, commented, “Submitting this IND is the most important milestone the Company has met thus far in the clinical development of our